Skip to main content
P

Plumbline Life Sciences, Inc. — Investor Relations & Filings

Ticker · 222670 ISIN · KR7222670002 KO Manufacturing
Open in API
Filings indexed 219 across all filing types
Latest filing 2026-04-03 Regulatory Filings
Country KR South Korea
Listing KO 222670

About Plumbline Life Sciences, Inc.

http://www.plsdna.com/

Plumbline Life Sciences, Inc. is an animal biopharmaceutical company that develops and manufactures drugs for animals based on an innovative DNA medicine platform technology. The company creates a new class of nucleic acid-based medicines that are designed to be potent, safe, and stable at room temperature, with a simplified manufacturing process. Its pipeline is focused on two primary areas: therapeutics for companion animals and vaccines for farm animals. A key product is 'RenewDog', a first-in-class DNA therapeutic developed for aging dogs.

Recent filings

Filing Released Lang Actions
단일판매ㆍ공급계약체결(자율공시)
Regulatory Filings Classification · 1% confidence The document is a voluntary self-disclosure (자율공시) of a single sales/supply contract between the company and a third party. It is not a financial report (e.g., 10-K, IR), not an earnings release, not a board or management change, not a share issuance, and not covered by any more specific category. Therefore it falls into the general regulatory announcement category (RNS).
2026-04-03 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an announcement of the annual general meeting (AGM) results for Plumline Life Sciences, detailing vote outcomes (찬성률, 가결여부) on various shareholder proposals (approval of financial statements, election of directors, remuneration limits, etc.). It is not the AGM materials or full annual report itself, but the official declaration of voting results at a general meeting. This matches the category “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-03-31 Korean
기타시장안내 (상장폐지 관련 이의신청서 접수 및 개선기간 부여)
Delisting Announcement Classification · 1% confidence The document is a Korean market notice titled “기타시장안내(상장폐지 관련 이의신청서 접수 및 개선기간 부여)”, which describes that the company’s capital is fully eroded, that a delisting reason has occurred, an appeal was filed on March 24, 2026, and the exchange granted an improvement period and trade suspension until a final delisting decision. This is an official notice concerning the delisting process of the company’s shares. Therefore, it matches the “Delisting Announcement” category.
2026-03-24 Korean
주권매매거래정지기간변경 (개선기간 부여)
Regulatory Filings Classification · 1% confidence The document is a brief regulatory announcement from the exchange detailing a change in the equity trading suspension period for a specific stock (Plumline Bioscience). It is not an annual or interim report, earnings release, management change, or any investor presentation. It simply notifies stakeholders of amended suspension dates under exchange rules. This falls under the generic “Regulatory Filings” category (RNS).
2026-03-24 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 1% confidence The document is a standalone audit report (“감사보고서”) including the independent auditor’s opinion, audit basis, responsibilities, and the full set of audited financial statements with notes. It does not include broader annual report narrative or management discussion. Therefore, it is classified as an Audit Report / Information. FY 2025
2026-03-23 Korean
기타시장안내 (상장폐지 관련)
Delisting Announcement Classification · 1% confidence The document is a short announcement regarding the delisting of Plumline Life Sciences due to capital impairment. It explicitly mentions '상장폐지' (delisting) and outlines the regulatory timeline for the delisting process. This fits the definition of a Delisting Announcement.
2026-03-20 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.